According to consensus projections compiled from Wall Street healthcare analysts covering Q32 Bio Inc., the average 12-month price target hovers around forty-two to forty-five United States dollars. Individual analyst forecasts span from a conservative low estimate of approximately thirty-six dollars up to an optimistic high estimate reaching fifty-nine to sixty-nine dollars per share. These bullish price targets reflect significant anticipated upside potential driven by clinical pipeline developments, specifically positive trial readouts for its lead therapeutic candidate targeting severe autoimmune conditions and alopecia areata.